Diagnostic value of antinuclear antibody spectrum detected with a fully automated BioPlexTM 2200 immunoassay analyzer in patients with systemic lupus erythematosus

doi:10.3877/cma.j.issn.1674-0785.2019.10.004

Abstract

Abstract:

Objective

To evaluate the value of antinuclear antibody (ANA) spectrum detected with a fully automated BioPlex 2200 immunoassay analyzer in the diagnosis of systemic lupus erythematosus (SLE).

Methods

We used a fully automated BioPlex^TM 2200 immunoassay analyzer and enzyme-linked immunosorbent assay (ELISA) method to detect dsDNA, Sm, and RNP antibodies in 30 cases of systemic lupus erythematosus. Fifteen ANAs were then detected with the fully automated BioPlex^TM 2200 immunoassay analyzer in 251 serum samples (including 109 from patients with SLE, 109 from patients with connective tissue disease, and 33 from healthy controls) and statistically analyzed. Other laboratory indexes were tested using routine methods.

Results

The positive rates of anti-dsDNA, anti-nuclear chromatin, anti-po, Sm, SmRNP, RNP, RNP68, SSA, RNP-A, Ro60, Ro52, and SSB had significant differences between the connective tissue disease group and healthy control group (P<0.05). The positive rate of CenB in the SLE group was comparable to those of the connective tissue disease group and healthy control group (P>0.05). There was a significant difference in the positive rate of any ANAs between the SLE group and the control group (P<0.05), but there was no significant difference between the connective tissue group and healthy control group (P>0.05). The two methods had a good consistency in the detection of dsDNA, Ro60, SSB, and Po (Kappa=0.79, 0.87, 0.76, and 0.80, respectively), and a fair consistency in the detection of Sm, RNP, and Ro52 (Kappa=0.61, 0.60, and 0.50, respectively).

Conclusion

Detection of antinuclear antibody spectrum with a fully automated BioPlex^TM 2200 immunoassay analyzer has appreciated clinical value in the diagnosis of SLE. The ability of flow matrix immunoluminescence assay to detect antinuclear antibody spectrum is comparable to that of ELISA.

Key words: Lupus erythematosus, systemic, Antibodies, antinuclear, Fully automated BioPlex 2200 immunoassay analyzer

Xinlan Pan, Zhijun Li, Chao Jiang, Ying Zhou, Mengjie Liu, Jiao Liu. Diagnostic value of antinuclear antibody spectrum detected with a fully automated BioPlex^TM 2200 immunoassay analyzer in patients with systemic lupus erythematosus[J]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(10): 736-739.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2019.10.004

https://zhlcyszz.cma-cmc.com.cn/EN/Y2019/V13/I10/736

Figures/Tables 2

References 13

1	Hanly JG, Thompson K, Mccurdy G, et al. Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus [J]. J Immunol Methods, 2010, 352(1-2): 147-152.
2	Maria I, Francesca M, Chelsea B, et al. Clinical comparison of QUANTA Flash dsDNA chemiluminescent immunoassay with four current assays for the detection of Anti-dsDNA autoantibodies [J]. J Immunol Res, 2015, 2015: 1-8.
3	Copple SS, Giles SR, Jaskowski TD, et al. Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization [J]. Am J Clin Pathol, 2012, 137(5): 825-830.
4	Metry AM, Al Salmi I, Al Balushi F, et al. Systemic lupus erythematous: symptoms and signs at initial presentations [J]. 2019, 18(2): 1-8.
5	Rekvig OP. Antiinflamm antiallergy agents med chem. The dsDNA, Anti-dsDNA antibody, and lupus nephritis: what we agree on, what must be done, and what the best strategy forward could be [J]. Front Immunol, 2019, 10: 1104.
6	Matus S, Burgos PV, Bravo-Zehnder M, et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis [J]. J Exp Med, 2007, 204(13): 3221-3234.
7	Zhou X, Chen H, Wei F, et al. 3β-Acetyloxy-oleanolic acid attenuates pristane-induced lupus nephritis by regulating th17 differentiation [J]. J Immunol Res, 2019(3): 2431617.
8	Au EY, Ip WK, Lau CS. Evaluation of a multiplex flow immunoassay versus conventional assays in detecting autoantibodies in systemic lupus erythematosus [J]. Hong Kong Med J, 2018, 24(3): 261-269.
9	Mahler M, Fritzler MJ. Anti-dsDNA antibody testing in the clinic: Farr or ELISA? [J]. Nat Clin Pract Rheumatol, 2007, 3(2): 72-73.
10	Fiegel F, Buhl A, Jaekel HP, et al. Autoantibodies to double-stranded DNA-Intermethod comparison between four commercial immunoassays and a research biosensor-based device [J]. Lupus, 2010, 19(8): 957-964.
11	江超, 王健, 周瀛,等.BioPlex 2200全自动免疫分析仪检测血清中抗环瓜氨酸肽抗体的临床应用 [J]. 齐齐哈尔医学院学报, 2017, 38(24): 2918-2920.
12	Martinetti A, Miceli R, Sottotetti E, et al. Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens [J].Cancers (Basel), 2014, 6(3): 1753-1768.
13	赵瀛, 黄斐, 宋斌斌, 等. BioPlex2200全自动免疫分析仪检测抗环瓜氨酸肽抗体的性能评估 [J]. 检验医学, 2014, 29(2): 153-157.

阳性指标	SLE组（n=109）	结缔组织病组（n=109）	对照组（n=33）
抗dsDNA	58（53.21）^ab	4（3.67）	0
抗核染色质	76（69.72）^ab	6（5.50）	0
抗核糖体P蛋白	30（27.52）^ab	1（0.92）	0
Sm	40（36.70）^ab	3（2.75）	0
SmRNP	65（59.63）^ab	7（6.42）	0
RNP	62（56.88）^ab	13（11.93）	1（3.03）
RNP68	33（30.28）^ab	3（2.75）	0
SSA	59（54.12）^ab	28（25.69）	0
RNP-A	54（49.54）^ab	12（11.01）	1（3.03）
Ro60	53（48.62）^ab	25（22.94）	0
Ro52	34（31.19）^ab	20（18.30）	0
SSB	17（15.60）^ab	7（6.42）	0
Scl70	11（10.09）^a	2（1.83）	0
CenB	4（3.67）	2（1.83）	0
Jo-1	0^a	2（1.83）	0
Any ANAs	106（97.24）^b	—	1（3.03）

阳性指标	SLE组（n=109）	结缔组织病组（n=109）	对照组（n=33）
抗dsDNA	58（53.21）^ab	4（3.67）	0
抗核染色质	76（69.72）^ab	6（5.50）	0
抗核糖体P蛋白	30（27.52）^ab	1（0.92）	0
Sm	40（36.70）^ab	3（2.75）	0
SmRNP	65（59.63）^ab	7（6.42）	0
RNP	62（56.88）^ab	13（11.93）	1（3.03）
RNP68	33（30.28）^ab	3（2.75）	0
SSA	59（54.12）^ab	28（25.69）	0
RNP-A	54（49.54）^ab	12（11.01）	1（3.03）
Ro60	53（48.62）^ab	25（22.94）	0
Ro52	34（31.19）^ab	20（18.30）	0
SSB	17（15.60）^ab	7（6.42）	0
Scl70	11（10.09）^a	2（1.83）	0
CenB	4（3.67）	2（1.83）	0
Jo-1	0^a	2（1.83）	0
Any ANAs	106（97.24）^b	—	1（3.03）

检测方法	抗dsDNA	Sm	RNP	Ro60	Ro52	SSB	CenB	Jo-1	Scl70	抗核糖体P蛋白
全自动分析法	20（66.67）	17（56.67）	15（50.00）	25（83.33）	17（56.67）	10（33.33）	0	0	0	15（50.00）
酶联免疫吸附法	17（56.67）	11（36.67）	15（50.00）	26（86.67）	22（73.33）	7（23.33）	0	0	0	12（40.00）
χ²值	1.33	4.17	—	0	2.29	1.33	—	—	—	1.33
P值	0.25	0.03	—	1	0.13	0.25	—	—	—	0.25

检测方法	抗dsDNA	Sm	RNP	Ro60	Ro52	SSB	CenB	Jo-1	Scl70	抗核糖体P蛋白
全自动分析法	20（66.67）	17（56.67）	15（50.00）	25（83.33）	17（56.67）	10（33.33）	0	0	0	15（50.00）
酶联免疫吸附法	17（56.67）	11（36.67）	15（50.00）	26（86.67）	22（73.33）	7（23.33）	0	0	0	12（40.00）
χ²值	1.33	4.17	—	0	2.29	1.33	—	—	—	1.33
P值	0.25	0.03	—	1	0.13	0.25	—	—	—	0.25

Please choose a citation manager

Content to export